Amarantus Bioscience Holdings Inc (AMBS)

[WarpCore61]

Back when Gerald set up Amarantus as a holding company and split the company into therapeutic and diagnostic divisions, he stated it was done as a strategic move so future transactions in one division would have no impact on the other division. He's also stated that he wears many hats, and that eventually the company will bring in someone to run the diagnostics division while he runs the therapeutic division.

Given the rapid growth and recent additions of assets within the diagnostics division, one possibility that comes closer to reality is a spinoff or sale of the diagnostics division. This could provide hundreds of millions of dollars to Amarantus to continue their work with MANF in the therapeutics division. Also, John Commissiong's statements in the recent CEO blog The Golden Goose: Preparing PhenoGuard to Lay the Next Golden Egg make it clear he is eager to return to discovering new neurotrophic factors. This is his passion... a true scientist, and highly respected in the field of neurology.

http://www.thechairmansblog.com/amarantus-bioscience/john-commissiong/golden-goose-preparing-phenoguard-to-lay-the-next-golden-egg/

While the diagnostics division is geared to provide the initial revenues to the company, a sale of this division would provide an immediate, massive cash influx to drive what is considered to be the real Golden Goose for the company.... the neurotrophic factors discovery and commercialization. It certainly seems like Gerald has been working overtime to significantly boost the value of the diagnostics division. Is that a precursor to a sale or spinoff of that division to fund his father's passion? It certainly seems like a distinct possibility to me.

To give credit where credit is due, I spoke with JPetro earlier today, and we discussed this possibility, and many of the thoughts I posted here are his thoughts and insights. Perhaps he can add more insight in areas I might have overlooked in this post.

Interesting times ahead, that's for sure. I'm glad to be an Amarantus investor in these early stages.